Bluebird Bio, a US-based gene therapy specialist, plans to float on the Nasdaq stock exchange with a market capitalization of about $328m. Bluebird plans to offer 5 million shares at between $14 and $16 each, with a further $750,000 shares available if demand is strong. Investment banks JP Morgan and BoA Merrill Lynch are Bluebird’s…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
